Document:

Exhibit
10.22a

 

ENSYSCE
BIOSCIENCES, INC. AMENDED AND RESTATED 2021 OMNIBUS INCENTIVE PLAN

 

STOCK
OPTION GRANT NOTICE AND

AWARD
AGREEMENT

 

Ensysce
Biosciences, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Amended and Restated Omnibus Incentive
Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase
the number of shares of Common Stock (the “Shares”) set forth below (the “Option”). The Option
described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth
in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated
herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings
defined in the Plan.

 

	Participant:	[_________]
	Grant
    Date:	[_________]
	Exercise
    Price Per Share:	[_________]
	Total
    Number of Shares Subject to Option:	[_________]
	Expiration
    Date:	[_________]
	Type
    of Option:	☐
    Incentive Stock Option (to the extent permitted by 422(d) of the Code)

                                                          

    ☐
    Non-Qualified Stock Option

	Vesting
    Schedule:	[_________]

 

By
signing below, Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and this Grant Notice. This document
may be executed, including by electronic means, in multiple counterparts, each of which will be deemed an original, and all of which
together will be deemed a single instrument.

 

	Ensysce
  biosciences, INC.	 	participant
	 	 	 	 	 
	 	 	 
	Name:	                 	 	Name:	                
	Title:	 	 	 	 

 

    	 

     

    

 

EXHIBIT
A

TO
STOCK OPTION GRANT NOTICE

 

AWARD
AGREEMENT

 

1.
Award of Option. Effective as of the Grant Date set forth in the Grant Notice, the Company has granted to Participant the Option
to purchase part or all of the aggregate number of Shares set forth in the Grant Notice, subject to the terms and conditions set forth
in the Grant Notice, the Plan and this Agreement.

 

2.
Term of Option. The Option may not be exercised later than the Expiration Date set forth in the Grant Notice, subject to earlier
termination in accordance with the Plan and this Agreement.

 

3.
Option Exercise Price. The exercise price per Share of the Option (the “Exercise Price”) is set forth in the
Grant Notice.

 

4.
Vesting and Exercise of Option. Subject to the continued service of Participant with the Company through the relevant vesting
dates, the Option shall become vested and exercisable in such amounts and at such times as set forth in the Grant Notice. In addition:

 

a.
Accelerated Vesting upon Death. Upon Participant’s Termination by reason of death, any portion of the Option that is outstanding
and unvested immediately prior to Participant’s death will fully vest and become exercisable on the date of Participant’s
death, provided that Participant’s estate and beneficiaries execute a general release of claims against the Company and its affiliates
in a form reasonably prescribed by the Company and such releases become irrevocable within forty-five (45) days following Participant’s
death. If the release requirement described above is not timely satisfied, any portion of the Option otherwise vesting under this Section
4.a will be forfeited. To the extent vested, the Option will be exercisable for the period of time set forth in Section 6.4(a) of the
Plan.

 

b.
Effect of Termination of Service on the Option. Unless otherwise provided in the Grant Notice, this Agreement or any written employment
agreement between Participant and the Company that expressly addresses treatment of stock option grants under the Plan, the termination
or survival of the Option upon the Termination of Participant will be determined in accordance with Section 6.4 of the Plan.

 

c.
Service with Affiliates. Solely for purposes of this Agreement, service with the Company will be deemed to include service with
an Affiliate of the Company (for only so long as such entity remains an Affiliate of the Company).

 

d.
Method of Exercise. Participant may exercise the Option only to the extent it is vested. To exercise the Option, Participant must
give written notice of exercise to the Company specifying the number of shares of Common Stock to be purchased, accompanied by payment
in full of the aggregate Exercise Price in accordance with Section 6.3(d) of the Plan. Such notice must specify the date (not to exceed
more than ninety (90) days after the date of such notice) on which the shares will be purchased and be accompanied by any further documents
or instruments the Company deems necessary or desirable to carry out the purposes or intent of this Agreement.

 

e.
Partial Exercise. The Option may be exercised in whole or in part, provided, however,
that the minimum number of Shares with respect to which the Option may be exercised is one hundred (100). If less than one hundred (100)
Shares remain outstanding under the Option at any time, the Option may only be exercised in whole. Any exercise may apply only with a
whole number of Shares.

 

    	1

     

    

 

f.
Conditions of Exercise. The Option may not be exercised, and any purported exercise will be void, if the issuance of Shares upon
such exercise would constitute a violation of any law, regulation, or exchange listing requirement. The Committee may from time to time
modify the terms of the Option or impose additional conditions on the exercise of the Option as it deems necessary or appropriate to
facilitate compliance with any law, regulation or exchange listing requirement.

 

g.
Rights as Stockholder. The Option will not confer upon Participant any of the rights or privileges of a stockholder in the Company
unless and until Participant is issued Shares following Participant’s exercise of the Option.

 

5.
Non-Transferability of Option. Participant may not anticipate, alienate, attach, sell, assign, pledge, encumber, charge or otherwise
transfer the Option other than by will or by the laws of descent and distribution. The Option shall be exercisable, during Participant’s
lifetime, only by Participant.

 

6.
Adjustments. The Exercise Price, as well as the number and kind of shares subject to the Option, are subject to adjustment in
accordance with Section 4.2 of the Plan.

 

7.
No Continuation of Service. Neither the Plan nor this Agreement will confer upon Participant any right to continue in the employment
or service of the Company or any of its Affiliates, or limit in any respect the right of the Company or its Affiliates to discharge Participant
at any time, for any reason.

 

8.
Withholding.

 

a.
Regardless of any action the Company takes with respect to any or all income tax, payroll tax or other tax-related withholding (“Tax-Related
Items”), Participant acknowledges that the ultimate liability for all Tax-Related Items owed by Participant is and remains
Participant’s responsibility and that the Company (i) makes no representations or undertakings regarding the treatment of any Tax-Related
Items in connection with any aspect of the Option, including the grant, vesting or exercise of the Option or the subsequent sale of Shares
acquired upon exercise; and (ii) does not commit to structure the terms of the grant or any aspect of the Option to reduce or eliminate
Participant’s liability for Tax-Related Items.

 

b.
Prior to exercise of the Option, Participant shall pay or make adequate arrangements satisfactory to the Company to satisfy all withholding
obligations of the Company. In this regard, Participant authorizes the Company to withhold all applicable Tax-Related Items legally payable
by Participant from Participant’s wages or other cash compensation paid to Participant by the Company or from proceeds of the sale
of the Shares. Alternatively, or in addition, to the extent permissible under applicable law, the Company may (i) sell or arrange for
the sale of Shares that Participant acquires to meet the withholding obligation for Tax-Related Items, and/or (ii) withhold Shares otherwise
issuable upon exercise of the Option, provided that the Company only withholds the amount of Shares necessary to satisfy the withholding
amount (not to exceed maximum statutory rates). Finally, Participant shall pay to the Company any amount of Tax-Related Items that the
Company may be required to withhold as a result of Participant’s participation in the Plan that cannot be satisfied by the means
previously described. The Company may refuse to issue and deliver Shares upon exercise of the Option if Participant fails to comply with
Participant’s obligations in connection with the Tax-Related Items as described in this Section 8.

 

9.
The Plan. A prospectus describing the Plan has been furnished to Participant. The Plan itself is available upon request, and its
terms and provisions are incorporated herein by reference. sPursuant to the Plan, the Committee is authorized to construe and interpret
the terms and provisions of the Plan and to adopt rules and regulations not inconsistent with the Plan as it deems necessary to carry
the Plan into effect. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee
with respect to questions arising under the Plan, the Grant Notice or this Agreement.

 

    	2

     

    

 

10.
Company Policies. Participant agrees, in consideration for the grant of the Option, to be subject to any policies by the Company
and its Affiliates regarding compensation recapture (i.e., clawbacks), securities trading, and hedging or pledging of securities that
may be in effect from time to time, or as may otherwise be required by applicable law, regulation or exchange listing standard.

 

11.
Entire Agreement. The Grant Notice and this Agreement, together with the Plan, represent the entire agreement between the parties
with respect to the subject matter hereof and supersede any prior agreement, written or otherwise, relating to the subject matter hereof.

 

12.
Amendment. This Agreement may only be amended by a writing signed by each of the parties hereto; provided that the Company may
amend this Agreement without Participant’s consent, if the amendment does not impair Participant’s rights hereunder or as
otherwise permitted in Section 4.f above.

 

13.
Governing Law. This Agreement will be construed in accordance with the laws and judicial decisions of the State of Delaware, without
regard to the application of the principles of conflicts of laws.

 

14.
Headings. The headings in this Agreement are for convenience only. They form no part of the Agreement and will not affect its
interpretation.

 

15.
Incentive Stock Options.

 

a.
If the Option is designated as an Incentive Stock Option, Participant acknowledges that nonetheless a portion of the Option may not qualify
(or may cease to qualify) as an “incentive stock option” under the Code due to limitations set forth in Section 422(d) of
the Code or otherwise. To the extent the Option does not qualify for treatment as an “incentive stock option” under the Code,
it will be treated as a Non-Qualified Stock Option. The Company does not guarantee any particular tax treatment for the Option or the
Shares subject to the Option.

 

b.
If the Option is designed as an Incentive Stock Option, Participant shall give prompt written notice to the Company of any disposition
or other transfer of any Shares acquired under the Option, if such disposition or transfer is made (i) within two years from the Grant
Date, or (ii) within one year after the transfer of such Shares to Participant. Such notice shall specify the date of such disposition
or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Participant
in such disposition or other transfer.

 

16.
Electronic Delivery of Documents. Participant authorizes the Company to deliver electronically any prospectuses or other documentation
related to the Option and any other compensation or benefit plan or arrangement in effect from time to time (including, without limitation,
reports, proxy statements or other documents that are required to be delivered to participants in such arrangements pursuant to federal
or state laws, rules or regulations). For this purpose, electronic delivery will include, without limitation, delivery by means of e-mail
or e-mail notification that such documentation is available on the Company’s Intranet site. Upon written request, the Company will
provide to Participant a paper copy of any document also delivered to Participant electronically. The authorization described in this
paragraph may be revoked by Participant at any time by written notice to the Company.

 

17.
Further Assurances. Participant agrees, upon demand of the Company or the Committee, to do all acts and execute, deliver and perform
all additional documents, instruments and agreements which may be reasonably required by the Company or the Committee, as the case may
be, to implement the provisions and purposes of this Agreement and the Plan.

 

18.
Restrictive Covenants. To the extent allowed by and consistent with applicable law and any applicable limitations period, if it
is determined at any time that Participant has materially breached any employment-related covenants, the Company will be entitled to
cause any unvested portion of the Option to be immediately cancelled without any payment of consideration by the Company.

 

    	3Exhibit
10.30c

 

SETTLEMENT
AGREEMENT AND MUTUAL GENERAL RELEASE

 

This
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE (“Agreement”), is made and entered into effective this August
3, 2021 (the “Effective Date”), by and among DelMorgan Group LLC (“DelMorgan”) Globalist Capital,
LLC (“Globalist” and, together with DelMorgan, “Advisor”) and D. Lynn Kirkpatrick, Ph.D. (“Kirkpatrick”)
and Ensysce Biosciences, Inc. (the “Company”). Collectively, Advisor, Company, and Kirkpatrick are referred to
herein individually as a “Party” or collectively, as “Parties.” Capitalized terms used and not
otherwise defined herein shall have the meanings given to such terms in the Email Agreement (defined below).

 

WHEREAS,
on January 31, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among
Leisure Acquisition Corp. (“LACQ”), EB Merger Sub, Inc., a wholly owned subsidiary of LACQ (“Merger Sub”),
providing for, among other things, and subject to the terms and conditions therein, the business combination between LACQ and the Company
pursuant to the merger of Merger Sub with and into the Company, with the Company continuing as the surviving entity (the “Merger”);

 

WHEREAS,
on January 26, 2021, Company and Advisor amended their previous letter agreement dated as of March 6, 2020 (“Letter Agreement”)
and with an email agreement dated as of January 31, 2021 (the “Email Agreement”);

 

WHEREAS,
pursuant to the Email Agreement the Advisor agreed to accept 500,000 private placement warrants (as such term is defined in the prospectus
for LACQ’s initial public offering) (“Advisor Warrants”) and 500,000 shares of LACQ’s Common Stock, now
Ensysce Common Stock (the “Advisor Shares”), none of which shall be subject to any lock-up, immediately after the
closing of the Merger as its sole and complete compensation and consideration under the Agreement, including without limitation with
respect to the Share Purchase Agreement dated as of December 29, 2020 by and among Ensysce, GEM Global Yield LLC SCS and GEM Yield Bahamas
Limited;

 

WHEREAS,
the parties entered into Amendment No. 1 the Email Agreement (the “Amendment”) to provide that instead of the 500,000
private placement warrants Advisor was to receive at the close of the Merger, Advisor received 500,000 replacement warrants which included
restrictions on transferability;

 

WHEREAS,
a dispute has now arisen concerning the nature of the promises made by the Company and Kirkpatrick with respect to the Email Agreement
and the Amendment, which has resulting in the filing of the lawsuit styled as DelMorgan Group, LLC et al. v. Ensysce Biosciences,
Inc., et al., Los Angeles County Superior Court, Case Number 21 STCV25585 (the “Lawsuit”);

 

WHEREAS,
without admitting fault, the parties desire to enter into this Agreement to settle the Lawsuit, and in furtherance thereof to, among
other matters, provide for (a) the registration of the Advisor’s Shares and the shares underlying the Advisor Warrants and (b)
to provide for cashless exercise of the Advisor Warrants, and, in exchange therefor, (c) Advisor agrees to withdraw and dismiss with
prejudice the Lawsuit, as defined below;

 

NOW,
THEREFORE, in consideration of the foregoing and the mutual covenants contained in this Agreement, and for other good and valuable
consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1.
Registration of Shares of Common Stock. Ensysce shall include the Advisor Shares and the shares of Common Stock underlying
the Advisor Warrants on its Registration Statement on Form S-1 (“S-1”) to be filed with the Securities and Exchange
Commission as soon as possible and in all events within ten days of the Effective Date. Ensysce shall use best efforts to have the S-1
declared effective as soon as possible following its filing and shall notify Advisor of the effectiveness of the S-1 at such time. For
the avoidance of doubt, the Advisor Warrants shall not be registered in the S-1, but the Common Stock underlying the Advisor Warrants
shall be registered in the S-1.

 

    	 

     

    

 

2.
Confirmation of Terms of Advisors Warrants. The Advisors Warrants shall be amended and restated to reflect an Exercise
Price of $10.00. The Advisor Warrants shall be deemed to have a “cashless exercise” feature, permitting the Advisor to exercise
using the cashless exercise feature found in the form Warrant Agreement filed with the SEC (Exhibit 4.1) in Section 3.3.1(c) and which
is set forth on Appendix A thereof.

 

3.
Dismissal of Lawsuit with Prejudice. Advisor agrees that the lawsuit filed in the Superior Court of Los Angeles County
on or about July 14, 2021, Case Number 21 STCV25585, filed by Del Morgan and Globalist, as Plaintiffs, and Ensysce and D. Lynn Kirkpatrick,
as Defendants (“Lawsuit”) shall be dismissed with prejudice within five business days of notification that the S-1 has become
effective. The dismissal shall request that the Court retain jurisdiction over this matter pursuant to California Code of Civil Procedure
§ 664.6 Upon full execution of this Agreement, DelMorgan shall file with the Court a Notice of Conditional Settlement, indicating
that the conditions to the settlement are likely to be satisfied within 45 days. Except as provided in Section 2 and 3 of this Agreement,
the Parties agree to stay any action on the Lawsuit after the S-1 is filed to allow for SEC review/effectiveness of the S-1 which the
Company agrees to use best efforts to seek effectiveness as soon as possible.

 

4.
Mutual General Releases. 

 

(a)
Release of Advisor. In consideration of the promises set forth in this Agreement, Kirkpatrick and Company, and each of them,
on behalf of their respective members, partners, representatives, attorneys, executors, administrators, successors, and assigns, hereby
releases, acquits, withdraws, and forever discharges Advisor and all of their members, partners, representatives, attorneys, executors,
administrators, successors, and assigns, from any and all actions, causes of action, obligations, costs, expenses, damages, losses, claims,
liabilities, suits, debts, demands, and benefits (including actual attorneys’ fees and costs), of whatever character, in law or
equity, known or unknown, suspected or unsuspected, matured or unmatured, of any kind or nature whatsoever, now existing or arising in
the future, based on any act, omission, event, occurrence or nonoccurrence from the beginning of time to the date of full execution of
this Agreement, arising from or related to the Letter Agreement, the E-Mail Agreement, the Amendment, or the Lawsuit.

 

(b)
Release of Company and Kirkpatrick. In consideration of the promises set forth in this Agreement, Advisor, and each of them,
on behalf of their members, partners, representatives, attorneys, executors, administrators, successors, and assigns, hereby releases,
acquits, withdraws, and forever discharges Advisor and all of their members, partners, representatives, attorneys, executors, administrators,
successors, and assigns, from any and all actions, causes of action, obligations, costs, expenses, damages, losses, claims, liabilities,
suits, debts, demands, and benefits (including actual attorneys’ fees and costs), of whatever character, in law or equity, known
or unknown, suspected or unsuspected, matured or unmatured, of any kind or nature whatsoever, now existing or arising in the future,
based on any act, omission, event, occurrence or nonoccurrence from the beginning of time to the date of full execution of this Agreement,
arising from or related to the Letter Agreement, the E-Mail Agreement, the Amendment, of the Lawsuit.

 

    	2

     

    

 

5.
Assumption of Risk and Waiver of Unknown Claims. For the purpose of implementing a full and complete release, the Parties
expressly acknowledge that the release they give in this Agreement is intended to include in its effect, without limitation, claims that
they did not know or suspect to exist in their favor at the time of the effective date of this Agreement, regardless of whether the knowledge
of such claims, or the facts upon which they might be based, would materially have affected the settlement of this matter, and that the
consideration given under this Agreement was also for the release of those claims and contemplates the extinguishment of any such unknown
claims. In furtherance of the settlement, the Parties waive any rights they may have under California Code of Civil Procedure §
1542 (and other similar statutes and regulations), which states:

 

“A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY.”

 

6.
Each Party to Bear Own Costs and Fees. Each Party shall bear their own attorneys’ fees and other costs (including
costs of expert witnesses or other consultants) incurred in relation to the Purchase Agreement and in the preparation, negotiation, and
drafting of this Agreement.

 

7.
Reaffirmation by Parties. The E-Mail Agreement, as expressly modified by the Amendment and this Agreement, shall
remain in full force and effect. The Letter Agreement, as expressly modified by the E-mail Agreement, the Amendment and this Agreement,
shall remain in full force and effect.

 

8.
Third Party Beneficiaries. Except as stated herein, there are no third-party beneficiaries to this Agreement.

 

9.
Comprehension of Agreement. By signing this Agreement, the Parties acknowledge that they have read it in its entirety and
represent and warrant that they understand it in its entirety.

 

10.
Representation by Counsel. The Parties hereto represent that they have received or had the opportunity to receive advice
from independent counsel of their own choice and have signed this Agreement freely and without duress.

 

11.
No Construction Against Drafter. Each of the Parties agree that each has participated in arriving at the final language
of this Agreement, and, therefore, this Agreement shall not be construed against any Party as drafter.

 

12.
Covenant to Take Further Actions Necessary. The Parties hereby agree to cooperate fully and to execute such other documents
and to take such other action as may be reasonably necessary to further the purpose of this Agreement, with the Parties to bear their
own costs and attorneys’ fees for these additional actions.

 

13.
Continuing Duty to Cooperate. The Parties hereto shall, at any time hereafter, make, execute, and deliver any and all papers
or documents as any Party hereto may reasonably require for the purpose of giving full effect to this Agreement and each of its provisions.

 

14.
Integrated Agreement. Expect as expressly stated herein, this Agreement sets forth the entire Agreement and understanding
between the Parties relating to the subject matter herein and supersedes all prior discussions between the Parties.

 

15.
Waiver, Modification, And Amendment. No modification or amendment to this Agreement shall be effective unless in writing
signed by the Parties’ whose rights or obligations are affected by such modification or amendment. Any subsequent change or changes
to any Party’s duties, obligations, rights, etc. shall not affect the validity or scope of this Agreement.

 

    	3

     

    

 

16.
Severability. If any provision of this Agreement or part thereof shall be held by a court or other tribunal of competent
jurisdiction to be unenforceable, then such provision or part thereof shall be excised here from and the remaining provisions of this
Agreement and parts thereof shall remain in full force and effect.

 

17.
Attorney’s Fees, Costs, and Enforcement. This Agreement shall be binding and enforceable under Code of Civil Procedure
Section 664.6. In any litigation, arbitration, or other proceeding in any way arising under or relating to this agreement, including
to enforce this contract (regardless of the nature of the claim) or to obtain a declaration of any rights or obligations under this contract,
the prevailing party shall be awarded its reasonable attorney fees, and costs and expenses incurred.

 

18.
Assignment of Claims. Each of the Parties represents to all other Parties that there has been no assignment or any transfer
of any right, title or interest in any claim, action, cause of action, obligation, or liability whatsoever that (i) a Party may have
or has had against any other Party hereto or (ii) authorized any other person or entity to assert such on its behalf, or (iii) is being
released pursuant to this Agreement.

 

19.
Authority. Each individual signing this Agreement warrants and represents that he or she has full authority to execute
the same on behalf of the Party on whose behalf he or she so signed, and that he or she is acting in the course and scope of such authority,
and is duly authorized to execute this Agreement.

 

20.
GOVERNING LAW. THIS AMENDMENT IS GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, WITHOUT
REGARD FOR THE PROVISIONS THEREOF REGARDING CHOICE OF LAW THAT WOULD APPLY THE LAW OF A DIFFERENT JURISDICTION.

 

21.
Multiple Counterparts. For the convenience of the parties hereto, this Agreement may be signed in multiple counterparts,
each of which will be deemed an original, and all counterparts hereof so signed by the parties hereto, whether or not such counterpart
will bear the execution of each of the Parties hereto, will be deemed to be, and is to be construed as, one and the same agreement. A
facsimile or electronic scan in “PDF” format of a signed counterpart of this Agreement will be sufficient to bind the Party
or Parties whose signature(s) appear thereon.

 

22.
Binding Effect; Assignment. This Agreement is binding upon, and will inure to the benefit
of and are enforceable by, the parties and their respective successors, representatives and permitted assigns. No Party to this Agreement
may assign this Agreement, by operation of law or otherwise, in whole or in part, without the prior written consent of the other parties,
and any purported assignment made or attempted in violation of this section will be null and void. 

 

[Signatures
Page Follows]

 

    	4

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be signed by their duly authorized officers as of the date first
above written.

 

	 	DELMORGAN
    GROUP LLC
	 	 	 
	 	By:
    	/s/
    Neil Morganbesser
	 	Name:
    	Neil
    Morganbesser 
	 	Title:
    	CEO
	 	 	 
	 	GLobalist
    capital, llc
	 	 	 
	 	By:
    	/s/
    Neil Morganbesser
	 	Name:
    	Neil
    Morganbesser 
	 	Title:
    	CEO
	 	 	 
	 	ENSYSCE
    BIOSCIENCES, INC.
	 	 	 
	 	By:	/s/
    Lynn Kirkpatrick
	 	 	Lynn
    Kirkpatrick
	 	 	Chief
    Executive Officer
	 	 	 
	 	D.
    LYNN KIRKPATRICK, Ph.D. 
	 	 	 
	 	 	/s/D.
    Lynn Kirkpatrick
	 	 	D.
    Lynn Kirkpatrick, Ph.D.

 

[Signature
Page to Settlement Agreement and Mutual General Release]

 

    	 

     

    

 

Appendix
A

 

Cashless
Exercise Feature. Upon surrender of the Advisor Warrant it shall receive that number of shares of Common Stock equal to the quotient
obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants multiplied by the difference between
the Warrant Price and the Fair Market Value by (y) the Fair Market Value. The Warrant Price shall mean $10.00 per share. The Fair Market
Value shall mean the average reported last sale price of the Common Stock for the ten trading days ending on the third trading day prior
to the date on which notice of the exercise of the Warrant is sent to the Warrant Agent.

 

By
way of example, if Warrants for 500,000 shares are tendered, the Warrant Price is $10.00 and the Fair Market Value is $20.00, then:

 

500,000
x (20.00 - 10.00)/20.00 = 250,000 shares of Common Stock would be issued in full satisfaction of the Advisor Warrant. The Common Stock
underlying the Advisor Warrants having been registered with the SEC are freely tradeable and without any further restriction on transfer.

 

[Signature
Page to Settlement Agreement and Mutual General Release]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]